Drug preserves visual acuity in patients with choroidal melanoma
Click Here to Manage Email Alerts
Aura Biosciences announced positive visual acuity results from a phase 1b/2 trial of its cancer drug AU-011 in patients with choroidal melanoma.
In the retrospective study, researchers compared data on visual acuity in patients treated with the drug (belzupacap sarotalocan, 43 patients) with data from a previous study on patients who underwent treatment with plaque radiotherapy (150 patients). both groups of patients were at high risk for vision loss and were matched for tumor height, diameter, distance from the fovea and baseline visual acuity.
Among patients in the radiotherapy study, data showed long-term, progressive loss in visual acuity in patients who had tumors close to the fovea.
Researchers found that AU-011 demonstrated better visual acuity preservation for both logMAR vision (P = .0094) and change in logMAR vision (P = .0323) as soon as 2 years, according to the release.
The company said the results show the need for vision-preserving therapy.
“We are committed to developing the first potential targeted therapy for patients with earlystage choroidal melanoma,” Aura hief edical fficer Cadmus Rich, MD, said in the release. “Belzupacap sarotalocan is currently being evaluated in a hase 2 doseescalation clinical trial using suprachoroidal administration in patients with earlystage choroidal melanoma. We remain on track to initiate our pivotal trial by the end of 2022.”
Read more about
Click Here to Manage Email Alerts